Key Highlights
• Shares traded at $317.04 pre-market, down 12.84% from the $363.76 prior close.
• Third-quarter Revenue reached $794 million, up about 34% year over year and ahead of roughly $707.5 million expected.
• Full-year 2026 revenue guidance was raised by about $140 million at the midpoint.
• Clinical MRD units reached about 316,000, up 56%.
• The per-share loss of $0.42 was wider than analysts had expected.
Natera (NASDAQ:NTRA) shares were trading lower in pre-market activity on Friday, November 6, after the company reported third-quarter 2026 results and announced a change in its chief executive. Steve Chapman is stepping down as CEO and will stay on as a consultant and board advisor. Solomon Moshkevich, a longtime executive, takes over the role. Management said the change came from a position of strength and that no major strategic shift is planned.
The company is an Austin, Texas-based provider of cell-free DNA testing and precision medicine. Its portfolio spans women's health, oncology and organ health, and most of its revenue comes from per-test reimbursement by Medicare and commercial insurers.
Quarterly Test Volumes and Pricing Move Higher
Third-quarter revenue of $794 million was up about 34% year over year and beat consensus of about $708 million by 12.22%. Oncology tests grew 61%, clinical test Volume reached about 1.1 million, up 22%, and Signatera's average selling price rose to about $1,290 from $1,271. Gross Margin was about 65%, or 63.2% excluding true-ups. Losses narrowed from the second quarter, although the per-share loss of $0.42 was wider than expected.
Blood-Based Cancer Testing Peers in Focus
Trading in the sector also reflected developments at peers. Grail (NASDAQ:GRAL) reported Galleri sales results, and Veracyte (NASDAQ:VCYT) saw a roughly 60% decline. Natera's rivals include Guardant Health (NASDAQ:GH) and Exact Sciences (NASDAQ:EXAS).
Full-Year Guidance Raised and a 2029 Revenue Goal Set
Management raised 2026 revenue guidance by about $140 million at the midpoint. It expects positive free Cash Flow for the year and improving EBITDA in the fourth quarter. The new long-term goal is $6 billion in revenue by 2029, roughly a 25% compound annual growth rate. The plan requires a Signatera average selling price of about $1,450.
What Comes Next: Reimbursement News, Pending Submissions and a 2027 Colorectal Readout
Several items are on the company's agenda. Japan Signatera reimbursement news is expected by the JPMorgan conference, nine to ten MolDX submissions are pending following the HCC coverage win, and the FIND colorectal readout is expected in 2027. For 2027, management assumes unit growth similar to 2026, steady average selling prices, and Operating Expense growth of 10% to 12%. Investors can track whether those milestones arrive on schedule and whether the 2027 assumptions hold under the new chief executive.






Please wait processing your request...